Balstilimab

In this video, Sandra D’Angelo, MD, discussed a phase 1b study on the efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma presented at the Connective Tissue Oncology Society Annual Meeting.

The FDA announced several regulatory actions the past few weeks.

In a video interview with Healio, Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, spoke about “the first combination to show efficacy in colorectal cancer in a specialized population.”

Balstilimab plus zalifrelimab demonstrated promising and durable activity among women with recurrent and/or metastatic cervical cancer who relapsed after platinum-based therapy, according to a phase 2 study in Journal of Clinical Oncology.

The FDA granted fast track designation to balstilimab for treatment of women with advanced cervical cancer.

The FDA granted fast track designation to balstilimab in combination with zalifrelimab for the treatment of women with relapsed or refractory metastatic cervical cancer, according to the agents’ manufacturer.